The chemical evolution of oligonucleotide therapies of clinical utility.
Reads0
Chats0
TLDR
As oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue.Abstract:
After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clinical productivity. One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chemical structure of the oligonucleotide whereas their target is defined by the base sequence. Thus, as oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue. To achieve clinical productivity, the chemical architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3'- and 5'-terminal modifications. A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chemical changes often translating into major improvements in clinical efficacy. One outstanding challenge in oligonucleotide chemical development is the optimization of chemical architectures to ensure long-term safety. There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop architectures that enable robust clinical efficacy in additional tissues.read more
Citations
More filters
Journal ArticleDOI
The current state and future directions of RNAi-based therapeutics.
TL;DR: This Review discusses key advances in the design and development of RNAi drugs leading up to this landmark achievement, the state of the current clinical pipeline and prospects for future advances, including novel RNAi pathway agents utilizing mechanisms beyond post-translational RNAi silencing.
Journal ArticleDOI
Therapeutic siRNA: state of the art.
TL;DR: In this review, the evolution of siRNA chemical modifications and their biomedical performance are comprehensively reviewed and all clinically explored and commercialized siRNA delivery platforms, including the GalNAc–siRNA conjugate, and their fundamental design principles are thoroughly discussed.
Journal ArticleDOI
Noncoding RNA therapeutics - challenges and potential solutions.
TL;DR: In this article, the authors discuss key challenges facing ncRNA therapeutics, including issues associated with specificity, delivery and tolerability, and focus on promising emerging approaches that aim to boost their success.
Journal ArticleDOI
Analysis of aptamer discovery and technology
TL;DR: A critical analysis of the first 25 years of aptamer research is provided to provide suggestions for choosing chemical modifications that can lead to enhanced activity or stability, and propose standards for the characterization of aptamers in the scientific literature.
Journal ArticleDOI
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen,David R. Corey +1 more
TL;DR: The chemical modifications and molecular mechanisms that make synthetic nucleic acid drugs possible and lessons learned from recent clinical trials will be summarized.
References
More filters
Journal ArticleDOI
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Andrew Fire,SiQun Xu,Mary K. Montgomery,Steven A. Kostas,Steven A. Kostas,Samuel E. Driver,Craig C. Mello +6 more
TL;DR: To their surprise, it was found that double-stranded RNA was substantially more effective at producing interference than was either strand individually, arguing against stochiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process.
Journal ArticleDOI
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
TL;DR: 21-nucleotide siRNA duplexes provide a new tool for studying gene function in mammalian cells and may eventually be used as gene-specific therapeutics.
Journal ArticleDOI
Functional siRNAs and miRNAs Exhibit Strand Bias
TL;DR: The results suggest that the thermodynamic properties of siRNA play a critical role in determining the molecule's function and longevity, possibly biasing the steps involved in duplex unwinding and strand retention by RISC.
Journal ArticleDOI
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis,Jonathan E. Zuckerman,Chung Hang Jonathan Choi,David Seligson,Anthony W. Tolcher,Christopher A. Alabi,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas +9 more
TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Journal ArticleDOI
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek,Akin Akinc,Birgit Bramlage,Klaus Charisse,Rainer Constien,Mary Donoghue,Sayda Elbashir,Anke Geick,Philipp Hadwiger,Jens Harborth,Matthias John,Venkitasamy Kesavan,Gary Lavine,Rajendra K. Pandey,Timothy Racie,Kallanthottathil G. Rajeev,Ingo Röhl,Ivanka Toudjarska,Gang Wang,Silvio Wuschko,David Bumcrot,Victor Koteliansky,Stefan Limmer,Muthiah Manoharan,Hans-Peter Vornlocher +24 more
TL;DR: In this article, chemically modified short interfering RNAs (siRNAs) were used to silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice.
Related Papers (5)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair,Jennifer L. S. Willoughby,Amy Chan,Klaus Charisse,Md. Rowshon Alam,Qianfan Wang,Menno Hoekstra,Pachamuthu Kandasamy,Alexander V Kel'in,Stuart Milstein,Nate Taneja,Jonathan O'Shea,Sarfraz Shaikh,Ligang Zhang,Ronald J. van der Sluis,Michael E. Jung,Akin Akinc,Renta Hutabarat,Satya Kuchimanchi,Kevin Fitzgerald,Tracy Zimmermann,Theo J.C. Van Berkel,Martin Maier,Kallanthottathil G. Rajeev,Muthiah Manoharan +24 more
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more